4 studies found for:    22595054 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Interventions: Biological: JNJ-64041809 (Cohort 1A and 1B);   Biological: JNJ-64041809 (Cohort 2A and 2B)
2 Recruiting Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: JNJ-64041757 (Cohort 1A and 1B);   Biological: JNJ-64041757 (Cohort 2A and 2B)
3 Recruiting Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: Immunotherapy plus chemotherapy;   Biological: Immunotherapy with cyclophosphamide plus chemotherapy
4 Active, not recruiting Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: GVAX Pancreas;   Biological: CRS-207;   Drug: Cyclophosphamide

Indicates status has not been verified in more than two years